Leptin and G-protein coupled receptor (GPCR) signaling: Therapeutic potential in obesity. [PDF]
J Biol ChemSun X +5 more
europepmc +1 more source
GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity. [PDF]
J Clin InvestCooper ME, van Raalte DH.
europepmc +1 more source
The Emerging Role of Glucagon-like Peptide 1 (GLP-1)-Based Medications in the Treatment of Heart Failure, with a Focus on Heart Failure with Preserved or Mildly Reduced Ejection Fraction. [PDF]
Medicina (Kaunas)Lee RSM +8 more
europepmc +1 more source
Nutrient-Stimulated Hormone Therapies in Heart Failure: Targeting Cardiometabolic Burden Beyond Weight Reduction. [PDF]
Int J Heart FailCho DH.
europepmc +1 more source
Amylin: From Mode of Action to Future Clinical Potential in Diabetes and Obesity. [PDF]
Diabetes TherVolčanšek Š +4 more
europepmc +1 more source
The Interplay Between GLP-1-Based Therapies, the Gut Microbiome, and MASLD/MASH in Type 2 Diabetes Mellitus: A Narrative Review. [PDF]
BiomedicinesDinkov B, Pendicheva-Duhlenska D.
europepmc +1 more source
Advancing Type 1 Diabetes Management: Integrating Novel Therapies, Technologies, and Adjunctive Approaches. [PDF]
Diabetes CareSnaith JR +4 more
europepmc +1 more source
Pancreatic amylin dynamically reconfigures distributed brain networks governing appetite regulation in mice. [PDF]
Mol MetabGezginer I +5 more
europepmc +1 more source
IUPHAR review: From foe to friend: Repurposing glucagon to treat obesity and type 2 diabetes. [PDF]
Pharmacol ResElmendorf AJ +5 more
europepmc +1 more source
The Obesity Drug Revolution: New Frontiers in Pharmacotherapy. [PDF]
CureusManoria PC.
europepmc +1 more source